In Segment C, contributors will get ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will receive treatment until illness progression or maybe the participants are not able to tolerate the study drugs. - Participant eaten grapefruit or grapef